SSRIs, Psilocybin, MDMA, and Disease Modeling: Strategies to Advance PTSD Treatment
Momoko Ishii, Mark Zervas
February 24, 2026 DOI: 10.14293/pr2199.003034.v1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Position paper |
|---|---|
| Population | General PTSD patients |
| Topics | Psilocybin MDMA PTSD |
| Keywords | Context archaeology Disease Multidisciplinary approach Therapeutic modalities Function biology Treatment modality Intensive care medicine Psychotherapist Position paper Biological neural network Neural activity |
| Key points | SSRIs, psilocybin, and MDMA act on serotonergic neural circuits and are used or proposed for PTSD, but their mechanisms at molecular, cellular, and neural circuit levels are still not well understood. |
Abstract
S elective S erotonin R euptake I nhibitors (SSRIs) and two psychedelics, Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine), and MDMA (3,4-Methylenedioxymethamphetamine) act on serotonergic-related neural circuits and function as serotonin modulators. All three molecules are either currently used or proposed as novel therapeutic modalities to treat P ost- T raumatic S tress D isorder (PTSD). While there are important clinical implications for treating PTSD, there are also a number of unanswered questions and still limited understanding of the mechanistic underpinnings of how these therapeutic modalities function at a molecular, cellular, and neural circuit level. Given their utility (e.g. SSRIs) and future consideration (e.g. Psilocybin, MDMA) for alleviating the complex symptoms of PTSD, a better understanding of their neurobiological role as well as their past and future intellectual property considerations are important converging topics. This review is a Position Paper by Zervas Scientific Consulting (ZSC) that places in context valuable and multidisciplinary topics to appropriately develop therapeutics with the ultimate goal of advancing effective novel treatment options for patients that currently live with PTSD.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Argues that SSRIs, psilocybin, and MDMA act on serotonergic circuits and are used or proposed for PTSD, but their mechanisms at molecular, cellular, and circuit levels remain poorly understood.
Synthesized